Velsecorat
Based on 3 publication(s) in Google Scholar
AZD7594 is a potent selective nonsteroidal glucocorticoid receptor modulator, with an IC50 of 0.9 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.83%
- CAS No.: 1196509-60-0
- Formule: C32H32F2N4O6
- Masse moléculaire:606.62
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Velsecorat
More
Activité biologique
Description
IC50 & Target
IC50: 0.9 nM (Glucocorticoid receptor)[1]
In Vitro
AZD7594 is a potent selective nonsteroidal glucocorticoid receptor modulator, with an IC50 of 0.9 nM. AZD7594 shows no effect on progesterone receptor, mineralocorticoid receptor, Androgen receptor, ERα or ERβ (IC50, > 10 μM).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1196509-60-0
-
Appearance Solid
-
Masse moléculaire 606.62
-
Formule C32H32F2N4O6
-
Color White to off-white
-
SMILES
O=C(N[C@H]1COCC1)C2=CC=CC(N3N=CC4=C3C=CC(O[C@H](C5=CC=C(OCCO6)C6=C5)[C@@H](NC(C(F)(F)C)=O)C)=C4)=C2
-
Synonyms
AZD7594; AZ13189620
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells. [Abstract]2025 Dec 2;122(48):e2517552122. PMID: 41289394 -
bioRxiv
Drug Repurposing Screen Identifies an HRI Activating Compound that Promotes Adaptive Mitochondrial Remodeling in MFN2-deficient Cells. [Abstract]2025 Jun 26:2025.06.23.660251. PMID: 40666974 -
Solvant et solubilité
In Vitro:
DMSO : ≥ 83.3 mg/mL (137.32 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6485 mL | 8.2424 mL | 16.4848 mL | 41.2120 mL |
| 5 mM | 0.3297 mL | 1.6485 mL | 3.2970 mL | 8.2424 mL | |
| 10 mM | 0.1648 mL | 0.8242 mL | 1.6485 mL | 4.1212 mL | |
| 15 mM | 0.1099 mL | 0.5495 mL | 1.0990 mL | 2.7475 mL | |
| 20 mM | 0.0824 mL | 0.4121 mL | 0.8242 mL | 2.0606 mL | |
| 25 mM | 0.0659 mL | 0.3297 mL | 0.6594 mL | 1.6485 mL | |
| 30 mM | 0.0549 mL | 0.2747 mL | 0.5495 mL | 1.3737 mL | |
| 40 mM | 0.0412 mL | 0.2061 mL | 0.4121 mL | 1.0303 mL | |
| 50 mM | 0.0330 mL | 0.1648 mL | 0.3297 mL | 0.8242 mL | |
| 60 mM | 0.0275 mL | 0.1374 mL | 0.2747 mL | 0.6869 mL | |
| 80 mM | 0.0206 mL | 0.1030 mL | 0.2061 mL | 0.5151 mL | |
| 100 mM | 0.0165 mL | 0.0824 mL | 0.1648 mL | 0.4121 mL |